AU2021310213A1 - HLA class II–restricted DRB T cell receptors against ras with g12d mutation - Google Patents

HLA class II–restricted DRB T cell receptors against ras with g12d mutation Download PDF

Info

Publication number
AU2021310213A1
AU2021310213A1 AU2021310213A AU2021310213A AU2021310213A1 AU 2021310213 A1 AU2021310213 A1 AU 2021310213A1 AU 2021310213 A AU2021310213 A AU 2021310213A AU 2021310213 A AU2021310213 A AU 2021310213A AU 2021310213 A1 AU2021310213 A1 AU 2021310213A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021310213A
Other languages
English (en)
Inventor
Gal CAFRI
Noam LEVIN
Steven A. Rosenberg
Rami Yoseph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2021310213A1 publication Critical patent/AU2021310213A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
AU2021310213A 2020-07-13 2021-07-13 HLA class II–restricted DRB T cell receptors against ras with g12d mutation Pending AU2021310213A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050931P 2020-07-13 2020-07-13
US63/050,931 2020-07-13
PCT/US2021/041375 WO2022015694A1 (en) 2020-07-13 2021-07-13 Hla class ii–restricted drb t cell receptors against ras with g12d mutation

Publications (1)

Publication Number Publication Date
AU2021310213A1 true AU2021310213A1 (en) 2023-03-09

Family

ID=77227130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021310213A Pending AU2021310213A1 (en) 2020-07-13 2021-07-13 HLA class II–restricted DRB T cell receptors against ras with g12d mutation

Country Status (8)

Country Link
US (1) US20230272038A1 (https=)
EP (1) EP4178976A1 (https=)
JP (1) JP2023534241A (https=)
KR (1) KR20230043881A (https=)
CN (1) CN116322734A (https=)
AU (1) AU2021310213A1 (https=)
CA (1) CA3185241A1 (https=)
WO (1) WO2022015694A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022227029A1 (en) 2021-02-26 2023-08-31 New York University Compositions and methods comprising antibodies that bind to covalent peptide conjugates
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150732A0 (en) * 2000-01-14 2003-02-12 Corixa Corp Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
EP3684799A1 (en) * 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras

Also Published As

Publication number Publication date
WO2022015694A8 (en) 2023-01-12
US20230272038A1 (en) 2023-08-31
KR20230043881A (ko) 2023-03-31
JP2023534241A (ja) 2023-08-08
CA3185241A1 (en) 2022-01-20
CN116322734A (zh) 2023-06-23
WO2022015694A1 (en) 2022-01-20
EP4178976A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
US20250250318A1 (en) Hla class ii-restricted t cell receptors against mutated ras
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20260008832A1 (en) Hla class ii-restricted t cell receptors against ras with g12r mutation
WO2021163477A1 (en) Hla class i-restricted t cell receptors against ras with g12v mutation
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
US20230272038A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12d mutation
US20230365649A1 (en) Hla class ii-restricted dq t cell receptors against ras with g13d mutation
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d
EP4326751A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation